Perioperative and periprocedural management of antithrombotic therapy: 2025 consensus document of SEC, SEDAR, SEACV, SECCE, AEC, SECOM CYC, SECPRE, SEPD, SEGG, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEN, S.E.N., SENEC, SEPAR, SEO, SEORL-CCC, SEPA, SERVEI, SECOT, and AEU.

Abstract

In recent years, the use of anticoagulant and antiplatelet medications has significantly increased, along with rising life expectancy. As a result, many patients on antithrombotic therapy will eventually require invasive procedures. This necessitates decisions on the appropriateness and timing of discontinuing anticoagulation and/or antiplatelet therapy in each case. Although a key multidisciplinary consensus document was published in 2018 to guide this process, its practical application has been limited. Furthermore, adherence to its recommendations has been low, leading to a higher incidence of both thrombotic and hemorrhagic adverse events. To address these issues and reflect advances in knowledge, it has been decided to update the previous consensus document to include developments since 2018. The aim is to simplify clinical decision-making and gain support from a broader range of scientific societies. Ultimately, the goal is to improve the dissemination and practical application of these recommendations to optimize the safety and effectiveness of antithrombotic treatment in patients requiring invasive procedures, reduce complications associated with inappropriate treatment, and enhance clinical outcomes in this increasingly complex scenario. Full English text available from: www.revespcardiol.org/en.